None listed
Conditions
Interventions
Low dose group (Group L): oliceridine fumarate 0.75mg + ciprofol:Oliceridine fumarate 0.75 mg was injected 3 min preoperatively, and then the anaesthesia was completed with the use of ciprofol, pushed
Medium dose group (Group M): oliceridine fumarate 1mg + ciprofol:Oliceridine fumarate 1 mg was injected 3 min preoperatively, and then the anaesthesia was completed with the use of ciprofol, pushed th
High-dose group (Group H): oliceridine fumarate 1.25mg + ciprofol:Oliceridine fumarate 1.25 mg was injected 3 min preoperatively, and then the anaesthesia was completed with the use of ciprofol, push
Sponsors
Affiliated Shunde Hospital of Jinan University
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age 18-60 years old; BMI 18-30 kg/m^2; Mallampati class I or II, no airway, head and neck condition abnormalities; ASA grade I or II; patients with elective proposed hysteroscopy; patients volunteered to participate in the study
Exclusion criteria
Exclusion criteria: Patients who refuse to participate or who are unfit to participate in this trial; allergy to ciprofol or oliceridine fumarate; severe cardiovascular, pulmonary, hepatic or renal dysfunction, or impaired adrenocortical function; history of alcohol or psychotropic or analgesic medication use within the last 24 h prior to surgery; airway hyperresponsiveness disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose of cyclobenzaprine per patient for positive (+) or negative (-) response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in vital signs at different time points;Ratio of total cypropofol dose to anaesthesia time;Physician satisfaction;recovery time and adverse reactions post-surgery;Patient comfort and satisfaction postoperatively; | — |
Countries
China
Contacts
Public ContactZhang Zhongqi
Affiliated Shunde Hospital of Jinan University
Outcome results
None listed